Premium
Potassium‐wasting nephropathy secondary to chemotherapy simulating bartter's syndrome
Author(s) -
Lieber Ira H.,
Stoneburner Seabury D.,
Floyd Michael,
McGuffin William L.
Publication year - 1984
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19840901)54:5<808::aid-cncr2820540507>3.0.co;2-y
Subject(s) - medicine , hypokalemia , vincristine , prednisone , chemotherapy , cyclophosphamide , gastroenterology , nephrotic syndrome , endocrinology , urology
A patient with a potassium wasting nephropathy secondary to chemotherapy simulating Bartter's syndrome is described. A 64‐year‐old woman with diffuse histiocytic lymphoma developed persistent hypokalemia following a course of Cytopan (cyclophosphamide), Adriamycin (doxorubicin), vincristine, and prednisone (CHOP)—Bleo. The diagnosis of a functional Bartter's syndrome was concluded following evaluation of serial plasma renins, aldosterone levels, and urinary electrolytes. Evidence is suggestive that a subpopulation of patients receiving chemotherapy may develop a functional Bartter's syndrome, and it is important to consider this diagnosis in patients who develop hypokalemia subsequent to chemotherapy introduction.